Meet the Experts
Bruce E Strober, MD, PhD
Department of Dermatology, Yale University, New Haven, CT, USA
Central Connecticut Dermatology Research, Cromwell, CT, USA
Dr Strober is Clinical Professor of Dermatology at Yale University School of Medicine, and practices at Central Connecticut Dermatology. He is also co-Scientific Director of the CorEvitas psoriasis registry, Secretary/Treasurer of the International Psoriasis Council, and Editor in chief of the Journal of Psoriasis and Psoriatic Arthritis.
Dr Strober earned both his medical degree and his doctorate from Columbia University College of Physicians and Surgeons in New York. He completed his residency in dermatology at the Department of Dermatology, New York University School of Medicine. He is certified by the American Board of Dermatology and is a Fellow of the American Academy of Dermatology.
Dr Strober's research interests include the study of therapeutics, both old and new, for inflammatory skin disease, specifically interventions that help patients with difficult-to-treat psoriasis, alopecia areata, atopic dermatitis, and hidradenitis suppurativa. He has served as principal investigator or sub-investigator for numerous multicenter clinical studies. His primary clinical focus is the treatment of moderate to severe plaque psoriasis and atopic dermatitis.
Dr Strober was Chair of the University of Connecticut Department of Dermatology from 2015–18. He has served as a Section Editor for the British Journal of Dermatology, and is an ad hoc reviewer for the Journal of the American Academy of Dermatology, JAMA Dermatology, British Journal of Dermatology, and Inflammation. He has published more than 160 book chapters and articles in peer-reviewed journals such as the New England Journal of Medicine, JAMA Dermatology, Journal of the American Academy of Dermatology, Journal of Investigative Dermatology, and the Journal of the American Medical Association, among others. Dr Strober also has presented data to the FDA on behalf of multiple pharmaceutical companies, including at the advisory committee for secukinumab.
Kenneth B Gordon, MD
Department of Dermatology, Medical College of Wisconsin,
Milwaukee, WI, USA
Kenneth Gordon is Thomas J Russell Family/Milwaukee Community Dermatologists Professor and Chair of Dermatology at the Medical College of Wisconsin, Milwaukee
Previously Dr Gordon served as Professor of Dermatology at Northwestern University, Feinberg School of Medicine (Chicago) and Associate Director, Center for Clinical Research of Northwestern University Center for Clinical and Translational Science
Dr Gordon received his medical degree from Columbia University, New York. In his position as a member of the American Academy of Dermatology (AAD), Dr Gordon has chaired several sessions at the annual meeting, and is on the Working Group on Psoriasis and Psoriatic Arthritis
Dr Gordon has published widely in several journals including the Journal of the American Academy of Dermatology and The Lancet, and he is a reviewer for others, such as the British Journal of Dermatology and the New England Journal of Medicine. His main research interests are therapies for psoriasis and psoriatic arthritis, and he contributed to the development of the AAD treatment guidelines for these diseases
Richard GB Langley, MD
Department of Medicine, Dalhousie University, Halifax, NS, Canada
Dr Langley is Professor and Director of Research in the Division of Dermatology, Department of Medicine, Dalhousie University, Canada, and was President of the Canadian Dermatology Association in 2014.
Dr Langley received his undergraduate degree at Dalhousie University, his internship in internal medicine and fellowship in dermatologic surgery at the University of Toronto, Canada, and completed his fellowship training at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Following his training, Dr Langley joined the Faculty of Medicine at Harvard Medical School, and was Director of Clinical Investigations Unit at Massachusetts General Hospital until June 2000.
Dr Langley has authored over 300 articles, book chapters, and other publications and he is a regular reviewer for several medical and dermatology journals. He is a principal investigator and has conducted over 250 Phase 1–3 studies involving most of the biologic agents in psoriasis and new immunotherapies in atopic dermatitis.
He also has an imaging laboratory that conducted the first studies with in vivo confocal microscopy in benign and malignant melanocytic lesions, and his continued to do original research in early diagnosis of cutaneous melanoma.
Richard Warren, MBChB (Hons), PhD
The University of Manchester, Manchester, UK
Richard Warren is a Clinical Professor and Honorary Consultant Dermatologist. He graduated from Liverpool University with a first-class honours degree in Pharmacology and gained his medical degree, with honours, 1 year later. He was awarded the J Hill Abram prize – highest mark in Medicine, and the Reginald Dora Goodrick prize – highest mark in Surgery.
Professor Warren’s work in dermatology has focused on pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility to psoriasis and, more recently, biologic therapies and their use for the treatment of psoriasis. For his research into the pharmacogenetics of methotrexate he has received national and international awards from the British Association of Dermatologists (BAD) and American Academy of Dermatology.
Professor Warren is widely published in the field of dermatology with more than 400 abstracts, papers and book contributions including 1st author papers in The New England Journal of Medicine and The Lancet. He is currently the EU Editor in Chief for the journal Dermatology and Therapy. He has been an invited plenary speaker at major national and international dermatology meetings and is a member of the International Psoriasis Council. He currently chairs the BAD guideline group for methotrexate and is a member of the BAD Biologics Committee and Research Subcommittee.
He is the current Director of the Dermatopharmacology Unit and has been/is the Global Chief Investigator on numerous clinical trials investigating new therapies for psoriasis and eczema. He co-established a clinic for patients with severe psoriasis and psoriatic arthritis in 2010 with Dr Hector Chinoy which has received wide acclaim and is used as a national exemplar.
Our directors are supported by an extensive network of global experts working in academia and community-based practices, providing both evidence-based and pragmatic perspectives.